GlassScriptPhysician profile
Farhad Mazdisnian
NPI 1750469201
$7,580.50
in general payments reported to CMS, 2019-2025
18 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $398 · 2021: $292 · 2022: $4,023 · 2023: $38.93 · 2024: $2,229 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Travel and Lodging: $604 · Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Travel and Lodging | $603.86 |
| Food and Beverage | $442.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,578.98 | 2022-2025 | Da Vinci Surgical System |
| Ethicon INC. | $1,069.36 | 2019-2022 | |
| Olympus America INC. | $184.05 | 2020-2025 | |
| Glaxosmithkline, LLC. | $165.01 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $125.79 | 2020-2024 | Imfinzi |
| Fujifilm Healthcare Americas Corporation | $113.54 | 2025 | |
| Mylan Specialty L.P. | $67.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $55.28 | 2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $44.26 | 2020-2021 | |
| Pulmonx Corporation | $34.07 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $31.60 | 2020 | |
| Circassia INC. | $20.21 | 2021 | |
| Chiesi USA, INC. | $19.35 | 2020 | |
| Pfizer INC. | $18.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $14.59 | 2020 | |
| Boston Scientific Corporation | $11.54 | 2020 | |
| Gilead Sciences, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Mazdisnian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.